Stay updated on Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FnGgDrqWcqvcQcH4QizVkRuJV0y4.uncropped.jpg&w=3840&q=75)
Latest updates to the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus related topics: Heart Failure Drug Information available for: Pioglitazone Pioglitazone hydrochloride FDA Drug and Device Resources Show less Design Details Primary Purpose : Health Services Research Allocation : Randomized Interventional Model : Parallel Assignment Interventional Model Description: Pioglitazone (15 mg) and dapagliflozin (10mg) vs Placebo Masking : Single ( Participant ) Masking Description: Random process Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Pioglitazone Plus dapaglifliozin Pioglitazone 15mg and dapagliflozin 10mg together in T2DM patients having HF and HFpEF conditions Drug : Pioglitazone Plus dapaglifliozin Pioglitazone Plus dapagliflozin Placebo Comparator : Placebo Beta blockers, ACEI, ARB, and aldosterone Drug : Placebo (Beta blockers, ACEI, ARB, and aldosterone ) Primary Outcome Measures Outcome Measure Measure Description Time Frame Time to first hospitalization for heart failure after starting intervention Hospitalization for heart failure will be defined as a hospitalization >24 hours requiring intravenous diuretic infusion. 3 years Secondary Outcome Measures Outcome Measure Measure Description Time Frame Number of all cause mortality Composite outcome comprised of total mortality, incidence of acute coronary syndrome and non fatal CVA 3 years Additional Relevant MeSH Terms Hypoglycemic Agents Physiological Effects of Drugs Pioglitazone Plan to Share Individual Participant Data (IPD)? No Studies a U.S. FDA-Regulated Drug Product No Studies a U.S. FDA-Regulated Device Product No Revision: v2.9.1SummaryDifference9%
Stay in the know with updates to Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.